[PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?].
BACKGROUND
Peroxisome proliferator-activated receptor agonists are used as an antidiabetic drug with particular effect on insulin sensitivity.


METHODS
This paper is based upon own literature and a Medline search.


CONCLUSIONS
The drug improves insulin sensitivity, but has several cardiovascular effects as well. Blood pressure, serum lipids, endothelial function, inflammation and growth of smooth muscle are all modulated by these agonists. This group of drugs shows constant antiatherosclerotic properties. Larger clinical studies will give the answer whether this treatment can reduce micro- and macro-vascular complications in diabetes.
Os
Ingrid
I
Nyremedisinsk avdeling, Ullevål universitetssykehus, og Fakultetsdivisjon Ullevål, Universitetet i Oslo, 0407 Oslo. ingrid.os@medisin.uio.no
D000419:Albuminuria; D050197:Atherosclerosis / Q000517:prevention & control; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000517:prevention & control; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D008074:Lipoproteins / Q000378:metabolism; D047495:PPAR gamma / Q000187:drug effects*; D000077205:Pioglitazone; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
D007004:Hypoglycemic Agents; D007328:Insulin; D008074:Lipoproteins; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D005947:Glucose; D000077205:Pioglitazone